
Biopharma News | Today's Latest Stories | Reuters
2 days ago · U.S. President Donald Trump and nine major pharmaceutical companies on Friday announced deals that will slash the prices of their medicines for the government's Medicaid …
Contract Pharma’s Top Breaking News Stories of 2025
1 day ago · Here’s your yearly recap—the most viewed breaking news stories on our site for 2025. This year, Contract Pharma readers gravitated toward stories that reflected a year …
Fierce Pharma Biopharma News & Insights
Oct 2, 2025 · Fierce Pharma delivers breaking news and analysis about drug companies, the FDA and the broader pharma industry, including manufacturing, marketing and finance.
News | Timely industry updates for pharma and biotech leaders
2 days ago · pharmaphorum’s news coverage updates daily with the latest pharma and biotech stories, from funding and M&A to regulatory approvals and policy shifts.
Pharma Sector News | PharmaVoice
6 days ago · Big Pharma needs new products to replenish pipelines and has plenty of money in the coffers, but looming uncertainties could stymie dealmaking again. With great power comes …
Citeline News & Insights | Expert Analysis in Pharma, Biotech, …
Dec 18, 2025 · In-depth global journalism and expert analysis of the pharma, biotech, medtech, and consumer health industries. We go beyond the headlines to deliver news with context and …
Pharmaceuticals sector - Financial Times
Dec 10, 2025 · Comprehensive coverage of the pharmaceuticals industry. The latest news and developments from the world's leading drug companies, including Pfizer, Johnson & Johnson, …
Pharma, Biotech and Generics Industry News | The Pharmaletter
Dec 17, 2025 · Up to date news for the pharmaceutical and biotechnology industries - The Pharma Letter
Pharmaceuticals News -- ScienceDaily
Dec 2, 2025 · Research news on the pharmaceutical industry including new drugs and interventions.
PharmTech’s Top 10 Articles of 2025 | Pharmaceutical Technology
1 day ago · Our top 10 articles of 2025 covered pharma tariffs, MFN deals, FDA leadership changes, 483 quality issues, and a soar in MASH competition.